Dr Conrad Savoy

President and Chief Executive Officer

Dr. Savoy was appointed President and CEO in May 2009 and has more than 18 years’ experience in development work in the pharmaceutical and biotech industry, leading several projects to EMEA approval. Dr. Savoy joined Biopartners in 2001 as Head of Pharma Development where he led the Valtropin (rhGH) development through to EU market authorization. In parallel he has managed the development of the sustained-release rhGH (SR-hGH), an innovative new formulation. In 2007 Dr. Savoy was promoted to Chief Scientific Officer.

Prior to joining Biopartners, Dr. Savoy spent 10 years at Hoffmann-La Roche in various senior positions, including Global Regulatory Affairs Leader. His responsibilities at Roche involved the design and implementation of development strategies for numerous novel chemical entities (NCE’s) and biopharmaceutical products during clinical development.  While at Roche, Dr. Savoy gained substantial experience in dealing with global regulatory authorities, including the FDA and the EMEA, and managed several projects reliant on the centralized European approval procedure. He holds an MBA from the Open University Business School, United Kingdom, and a PhD from the University of Basel, Switzerland.